{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:36:06Z","timestamp":1782146166707,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19K08726"],"award-info":[{"award-number":["19K08726"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10157-021-02099-4","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T12:02:59Z","timestamp":1623672179000},"page":"1224-1230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay"],"prefix":"10.1007","volume":"25","author":[{"given":"Rini","family":"Rossanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"China","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Minamikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ishiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Aoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ninchoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"9","key":"2099_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","volume":"103","author":"A Mehta","year":"2010","unstructured":"Mehta A, et al. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641\u201359.","journal-title":"QJM"},{"key":"2099_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ. Fabry disease, an under-recognized multisystemic disorder:expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338\u201346.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2099_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/jhg.2011.31","volume":"56","author":"S Saito","year":"2011","unstructured":"Saito S, Ohno K, Sakuraba H. Fabry-database.org: database of the clinical phenotypes genotypes and mutant \u237a-galactosidase A sturctures in Fabry disease. J Hum Genet. 2011;56(6):467\u20138.","journal-title":"J Hum Genet"},{"key":"2099_CR4","volume-title":"Pharmagenesis","author":"M Fuller","year":"2006","unstructured":"Fuller M, Meikle P, Hopwood J. Epidemiology of lysosomal storage diseases: an overview, in Fabry Disease: perspectives from 5 Years of FOS. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Pharmagenesis. England: Oxford; 2006."},{"key":"2099_CR5","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.ymgmr.2019.100562","volume":"22","author":"T Sawada","year":"2020","unstructured":"Sawada T, et al. Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep. 2020;22:100562.","journal-title":"Mol Genet Metab Rep"},{"issue":"8","key":"2099_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58(8):548\u201352.","journal-title":"J Hum Genet"},{"issue":"1","key":"2099_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2099_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"P Deegan","year":"2006","unstructured":"Deegan P. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006;43(4):347\u201352.","journal-title":"J Med Genet"},{"key":"2099_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11:790\u20136.","journal-title":"Genet Med"},{"key":"2099_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, et al. The Main Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299\u2013307.","journal-title":"Clin Genet"},{"key":"2099_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","volume":"505","author":"D Elstein","year":"2012","unstructured":"Elstein D, et al. X-inactivation in Fabry disease. Gene. 2012;505:266\u20138.","journal-title":"Gene"},{"key":"2099_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/ajmg.a.30123","volume":"129A","author":"W Dobyns","year":"2004","unstructured":"Dobyns W, et al. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet. 2004;129A:136\u201343.","journal-title":"Am J Med Genet"},{"key":"2099_CR13","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1111\/j.1749-6632.2010.05943.x","volume":"1214","author":"C Morey","year":"2010","unstructured":"Morey C, Avner P. Genetics and epigenetics of the X chromosome. Ann N Y Acad Sci. 2010;1214:E18-33.","journal-title":"Ann N Y Acad Sci"},{"key":"2099_CR14","first-page":"1","volume":"20","author":"MA Hossain","year":"2019","unstructured":"Hossain MA, et al. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene. Mol Genet Metab Rep. 2019;20:1\u20137.","journal-title":"Mol Genet Metab Rep"},{"issue":"8","key":"2099_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","volume":"83","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R. Relationship between X-inactivation and clinical in- volvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl). 2005;83(8):647\u201354.","journal-title":"J Mol Med (Berl)"},{"issue":"451","key":"2099_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08035320600618809","volume":"95","author":"E Maier","year":"2006","unstructured":"Maier E. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl. 2006;95(451):30\u20138.","journal-title":"Acta Paediatr Suppl"},{"key":"2099_CR17","first-page":"1229","volume":"51","author":"RC Allen","year":"1992","unstructured":"Allen RC, Zoghbi HY, Moseley A, Rosenblatt HF, Belmont J. Methylation of Hpall and Hhal sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229\u201339.","journal-title":"Am J Hum Genet"},{"key":"2099_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s10038-018-0415-1","volume":"63","author":"S Minamikawa","year":"2018","unstructured":"Minamikawa S, et al. Development of ultra-deep targeted RNA sequencing for analyzing X-chromosome inactivation in female Dent disease. J Hum Genet. 2018;63:589\u201395.","journal-title":"J Hum Genet"},{"issue":"5","key":"2099_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfw082","volume":"9","author":"R Mignani","year":"2016","unstructured":"Mignani R, et al. FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease. Clin Kidney J. 2016;9(5):739\u201347.","journal-title":"Clin Kidney J"},{"issue":"6","key":"2099_CR20","first-page":"1229","volume":"51","author":"R Allen","year":"1992","unstructured":"Allen R, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen receptor gene correlates With X Chromosome Inactivation. Am J Hum Genet. 1992;51(6):1229\u201339.","journal-title":"Am J Hum Genet"},{"key":"2099_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, et al. Multicenter Female Fabry Study (MFFS)\u2014clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11:88.","journal-title":"Orphanet J Rare Dis"},{"key":"2099_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:1\u201349.","journal-title":"Orphanet J Rare Dis"},{"key":"2099_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"2099_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet"},{"key":"2099_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, et al. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120:57\u201361.","journal-title":"Mol Genet Metab"},{"key":"2099_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.gene.2017.10.064","volume":"641","author":"P Juchniewicz","year":"2018","unstructured":"Juchniewicz P, et al. Female Fabry disease patients and X-chromosome inactivation. Gene. 2018;641:259\u201364.","journal-title":"Gene"},{"key":"2099_CR27","first-page":"1","volume":"2015","author":"FO Arcolino","year":"2014","unstructured":"Arcolino FO, et al. Human urine as a noninvasive source of kidney cells. Stem Cell Int. 2014;2015:1\u20137.","journal-title":"Stem Cell Int"},{"key":"2099_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/clinchem\/46.8.1078","volume":"46","author":"I Botezatu","year":"2000","unstructured":"Botezatu I, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000;46:1078\u201384.","journal-title":"Clin Chem"},{"key":"2099_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1749-6632.2001.tb03892.x","volume":"945","author":"A Lichtenstein","year":"2001","unstructured":"Lichtenstein A, et al. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci. 2001;945:239\u201349.","journal-title":"Ann N Y Acad Sci"},{"key":"2099_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jmg.2007.055244","volume":"45","author":"D Bittel","year":"2008","unstructured":"Bittel D, et al. Comparison of X-chromosome inactivation patterns in multiple tissues from human females. J Med Genet. 2008;45:309\u201313.","journal-title":"J Med Genet"},{"key":"2099_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s004390000382","volume":"107","author":"A Sharp","year":"2000","unstructured":"Sharp A, Robinson D, Jacobs P. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet. 2000;107:343\u20139.","journal-title":"Hum Genet"},{"key":"2099_CR32","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1182\/blood.V83.10.2899.2899","volume":"83","author":"R Gale","year":"1994","unstructured":"Gale R, et al. Tissue specificity of X-chromosome inactivation patterns. Blood. 1994;83:2899\u2013905.","journal-title":"Blood"},{"key":"2099_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/BF02185765","volume":"97","author":"J Azofeifa","year":"1996","unstructured":"Azofeifa J, Waldherr R, Cremer M. X-chromosome methylation ratiosas indicators of chromosomal activity: evidence of intraindividual diver-gencies among tissues of different embryonal origin. Hum Genet. 1996;97:330\u20133.","journal-title":"Hum Genet"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02099-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-021-02099-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02099-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T10:17:26Z","timestamp":1632392246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-021-02099-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1007\/s10157-021-02099-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-100840\/v1","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"6 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kandai Nozu has received lecture fees from Sumitomo Dainippon Pharma. Atsushi Fukunaga has received lecture fees from Sumitomo Dainippon Pharma and Sanofi K.K. Kazumoto Iijima has received lecture fees from Sanofi K.K. Hideki Fujii has received lecture fees from Sumitomo Dainippon Pharma, Sanofi K.K., and Amicus Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were reviewed and approved by the Institutional Review Board of Kobe University Graduate School of Medicine (IRB approval number 019-301) and performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent for conducting this study was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}